hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06379412 id: Zhujianghmy briefTitle: A Cross-sectional Study on the Association of Peptidoglycan Fragments Derived From Gut Microbiota With Colorectal Cancer overallStatus: RECRUITING date: 2023-07-01 date: 2024-12 date: 2024-12 date: 2024-04-23 date: 2024-04-26 name: Zhujiang Hospital class: OTHER briefSummary: The goal of this observational study is to explore the association of peptidoglycan fragments derived from gut microbiota with colorectal cancer (CRC). The main question it aims to answer is: Are peptidoglycan fragments from the gut microbiota associated with the progression of colorectal cancer? Participants will provide biological specimens (blood, feces, colon tissue obtained during surgery) conditions: Colorectal Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 200 type: ESTIMATED name: observational study, no intervention measure: HPLC-MS/MS was used to detect peptidoglycan fragment content in biological specimens of 200 participants sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Zhujiang Hospital of Southern Medical University status: RECRUITING city: Guangzhou state: Guangdong zip: 510000 country: China name: He Xiaolong, Professor role: CONTACT phone: 186 2007 1640 email: 307660349@qq.com lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06379399 id: IRB-2023-1072 briefTitle: Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC overallStatus: RECRUITING date: 2024-04 date: 2025-03 date: 2025-12 date: 2024-04-23 date: 2024-04-23 name: Wangxia LV class: OTHER briefSummary: This study is a single-center, prospective, single-arm exploratory study aimed at evaluating the efficacy and safety of trifluridine/tipiracil in combination with cetuximab in the treatment of third-line and above RAS/BRAF wild-type metastatic colorectal cancer. conditions: Colorectal Cancer Metastatic studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 26 type: ESTIMATED name: Cetuximab name: Trifluridine/Tipiracil measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Overall Response Rate (ORR) measure: Disease Control Rate( DCR) measure: Quality of life: EORTC QLQ-C30 measure: Adverse Events(safety) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Zhejiang Cancer Hospital status: RECRUITING city: Hangzhou state: Zhejiang zip: 310022 country: China name: Wangxia Lv role: CONTACT phone: +86-13757141026 email: lvwangxia@163.com lat: 30.29365 lon: 120.16142 hasResults: False
nctId: NCT06379386 id: TRACE TAVR Registry briefTitle: Long-term Prognosis and Valve Durability of TAVR overallStatus: RECRUITING date: 2016-01 date: 2025-12 date: 2030-12 date: 2024-04-23 date: 2024-04-23 name: Xijing Hospital class: OTHER briefSummary: This registry aims to evaluate the long-term prognosis and valve durability of transcatheter aortic valve replacement (TAVR) in a real-world setting. Baseline characteristics, procedural data, and clinical outcomes will be collected in a prospective and observational manner. conditions: Aortic Valve Stenosis and Insufficiency studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1000 type: ESTIMATED name: Transcatheter aortic valve replacement measure: All-casuse mortality measure: Valve-related long-term clinical efficacy measure: Combined early safety and clinical efficacy outcomes measure: Rate of technical success measure: Rate of device success measure: Combined clinical efficacy outcomes measure: Valve-related long-term clinical efficacy sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Xijing Hospital status: RECRUITING city: Xi'an state: Shannxi zip: 710032 country: China name: Rutao Wang, M.D., Ph.D. role: CONTACT phone: +86-15091095796 email: rutaowang@qq.com name: Ruining Zhang, BSc role: CONTACT phone: +86-15802990370 email: ruining-zhang@qq.com name: Ling Tao, M.D., Ph.D. role: PRINCIPAL_INVESTIGATOR lat: 34.25833 lon: 108.92861 hasResults: False
nctId: NCT06379360 id: SZAMLLRM01 briefTitle: Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients overallStatus: RECRUITING date: 2020-11-01 date: 2024-05-01 date: 2028-12-31 date: 2024-04-23 date: 2024-04-24 name: The First Affiliated Hospital of Soochow University class: OTHER briefSummary: HMA maintenance therapy is expected to benefit overall survival (OS) and relapse free survival (RFS) in AML patients with favorable risk. conditions: Acute Myeloid Leukemia studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Apply hypomethylating agent, azacitidine or decitabine as maintenance therapy. primaryPurpose: TREATMENT masking: NONE count: 77 type: ESTIMATED name: Hypomethylating agent, Azacitidine or Decitabine measure: Relapse free survival (RFS) measure: Overall survival (OS) measure: Cumulative incidence of relapse (CIR) sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: The First Affiliated Hospital of Soochow University status: RECRUITING city: Suzhou state: Jiangsu zip: 215006 country: China name: Sheng-Li Xue, M.D. role: CONTACT phone: +86 512 6778 1139 email: slxue@suda.edu.cn lat: 31.30408 lon: 120.59538 hasResults: False
nctId: NCT06379347 id: FZ 23/41 briefTitle: HOspitalized Patients and Clinical flUid Status, Assessment Using Point Of Care UltraSound acronym: HOCUS-POCUS overallStatus: RECRUITING date: 2024-02-28 date: 2025-03 date: 2025-03 date: 2024-04-23 date: 2024-04-23 name: Flevoziekenhuis class: OTHER briefSummary: Point of care ultrasound (POCUS) of the inferior vena cava (IVC) is a tool for assessing volume status through ultrasonography. Using a point of care ultrasound device, the physician can perform an ultrasound of the vena cava at the bedside. Previous research has demonstrated a correlation between right atrial pressure and the vena cava's diameter. Nonetheless, the majority of research has been conducted in critically ill populations to predict fluid responsiveness in patients with more complex hemodynamics. There is limited data available on the value of IVC ultrasound in the sub-acute setting on the regular ward for clinical decision-making regarding whether a patient is hypovolemic or hypervolemic. This study's objective is to assess the diagnostic utility of point-of-care ultrasonography of the IVC, by using a standardized methodology, performed by qualified ward physicians in a conventional nursing ward. conditions: Volume Status studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: POCUS perfomed on clinica indication measure: Volume status sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Flevoziekenhuis status: RECRUITING city: Almere country: Netherlands name: Koen de Heer, MD PhD role: CONTACT lat: 52.37535 lon: 5.25295 hasResults: False
nctId: NCT06379334 id: I-22PJ911 briefTitle: Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B Population overallStatus: ACTIVE_NOT_RECRUITING date: 2020-12-06 date: 2024-12-06 date: 2026-12-06 date: 2024-04-23 date: 2024-04-23 name: Peking Union Medical College Hospital class: OTHER briefSummary: Chronic hepatitis B (CHB) can lead to hepatocellular carcinoma (HCC), imposing a significant health and economic burden globally. Early detection of hepatitis B virus-related HCC (HBV-HCC) in CHB with potential biomarkers has become a pressing and difficult challenge. Recent advancements in urinary proteomics offer a promising approach for HBV-HCC biomarker identification, utilizing Liquid chromatography with tandem mass spectrometry for urine proteome analysis. Differential analysis using limma in R software will uncover upregulated proteins in HBV-HCC. conditions: Hepatocellular Carcinoma conditions: Hepatitis B studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 180 type: ESTIMATED name: Urine test measure: upregulated proteins measure: downregulated proteins sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Peking Union Medical College Hospital city: Beijing country: China lat: 39.9075 lon: 116.39723 hasResults: False
nctId: NCT06379321 id: 24-362 briefTitle: A Retrospective/Prospective, Post-market Evaluation of Outcomes of the Triathlon Hinge Knee (THK) System acronym: Hinge overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2034-05-01 date: 2034-05-01 date: 2024-04-23 date: 2024-04-23 name: The Cleveland Clinic class: OTHER name: Stryker Orthopaedics briefSummary: This study is a prospectively and retrospectively enrolled, post-market, open-label, non-randomized, single institution evaluation of clinical outcomes of primary or revision knee surgery patients who meet the eligibility criteria and received devices from the Triathlon Hinge Knee System according to its indications for use (IFU).
Clinical evaluation for all cases will include data collection of patient demographics, surgical details, early postoperative status, functional and clinical outcomes, and survivorship at 1, 2, 6, and 10-years. conditions: Knee Arthropathy conditions: Recurrence conditions: Knee Infection studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 200 type: ESTIMATED name: Triathlon Hinge Knee (THK) System measure: Survivorship sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Cleveland Clinic Florida city: Weston state: Florida zip: 33331 country: United States name: Kaitlin Bernabe role: CONTACT phone: 954-610-8016 email: BERNABK@ccf.org name: Jorge Manrique-Succar role: PRINCIPAL_INVESTIGATOR lat: 26.10037 lon: -80.39977 facility: Cleveland Clinic city: Cleveland state: Ohio zip: 44195 country: United States name: Laura Stiegel role: CONTACT phone: 216-442-5511 email: stiegel@ccf.org name: Alison Klika role: CONTACT phone: 216 444-4954 email: klikaa@ccf.org name: Matthew Deren, M.D. role: PRINCIPAL_INVESTIGATOR lat: 41.4995 lon: -81.69541 hasResults: False
nctId: NCT06379308 id: IRBN552024/CHUSTE. briefTitle: Anterior Cruciate Ligament (ACL) Revision Surgery: French National Study overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2027-04 date: 2024-04-23 date: 2024-04-23 name: Centre Hospitalier Universitaire de Saint Etienne class: OTHER briefSummary: This is a national multicentric study led by the French Arthroscopy Society (SFA) evaluating clinical practice in anterior cruciate ligament (ACL) revision surgery (epidemiological data, morphological data, operative data, clinical and functional outcomes, and surgical complication rates). conditions: Anterior Cruciate Ligament Rupture studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED name: questionaries name: datas of medical record measure: Results of Functional score questionary Anterior Cruciate Ligament Return to Sport and Injury (ACL-RSI) measure: Results of Functional score questionary Tegner Activity Scale (TAS) measure: Results of Functional score questionary Simple Knee Value (SKV) measure: Results of Functional score questionary International Knee Documentation Commitee (IKDC) measure: Surgical complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHU Saint-Etienne city: Saint-Étienne country: France name: Thomas NERI, MD PhD role: CONTACT phone: (0)477120784 phoneExt: +33 email: thomas.neri@chu-st-etienne.fr name: Thomas NERI, MD PhD role: PRINCIPAL_INVESTIGATOR lat: 45.43389 lon: 4.39 hasResults: False
nctId: NCT06379295 id: CHUO-2024-05 briefTitle: Coronary Artery Calcification Assessed on PET/CT acronym: CALCOTEP overallStatus: NOT_YET_RECRUITING date: 2024-05-21 date: 2025-05-21 date: 2025-05-21 date: 2024-04-23 date: 2024-04-23 name: Centre Hospitalier Régional d'Orléans class: OTHER briefSummary: Calcification artery calcium (CAC) scoring is a valuable tool for determining the risk of major adverse cardiac events.
Each patient will complete a questionnaire to collect risk factors, history of cardiovascular diseases and medications. conditions: Coronary Artery Disease conditions: Coronary Artery Calcification studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 200 type: ESTIMATED name: Questionnaire measure: Prevalence of moderate CAC in participants without history of cardiac disease measure: Prevalence of coronary heart disease among participants measure: Correlation of CAC with the medical indication for PET imaging measure: Prevalence of CAC in young participants (< 45 years old) measure: Prevalence of moderate CAC in participants not taking low-cholesterol drug measure: Prevalence of no CAC in participants taking statins sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06379282 id: FHMS 21-22 263 EGA briefTitle: Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia acronym: HIT-CLL overallStatus: RECRUITING date: 2022-10-14 date: 2025-08-01 date: 2026-08-01 date: 2024-04-23 date: 2024-04-24 name: University of Surrey class: OTHER name: American Society of Hematology briefSummary: This randomised control clinical trial aims to investigate the effects of exercise training and diet on physical and functional fitness and immunological and metabolic changes in adults with chronic lymphocytic leukaemia. Investigators will randomise participants to either 12 weeks of supervised/semi-supervised exercise only, exercise + nutritional guidance, or no exercise. conditions: Chronic Lymphocytic Leukemia conditions: Frailty conditions: Muscle Function conditions: Immune Function conditions: Lipid Cell; Tumor studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Recruited participants will be randomised to either exercise only, exercise + nutritional guidance, or control for 12 weeks primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 132 type: ESTIMATED name: HIT name: EXE+ Nutritional Guidance measure: Change from baseline in absolute number of CD19+/CD5+ CLL cells at week 12 measure: Change from baseline in cardiorespiratory fitness (CRF: VO2peak) at week 12 measure: Frailty measure: Muscle Strength and Endurance measure: Muscle Health measure: Change in Quality of Life using the EORCT-QLQ-C30 measure: Change in muscle oxygen metabolism during a single bout of exercise measure: Change in B-CLL Cell Function measure: Change in systemic and cellular bioenergetics measure: Legacy Effect of Intervention on change in cardiorespiratory fitness (VO2peak) as measured by a cardiopulmonary exercise test measure: Legacy Effect of Intervention on absolute number of CD19+/CD5+ CLL cells sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Surrey status: RECRUITING city: Guildford zip: GU2 7WG country: United Kingdom name: David Bartlett, PhD role: CONTACT phone: 01483 683 45 email: d.bartlett@surrey.ac.uk lat: 51.23536 lon: -0.57427 hasResults: False
nctId: NCT06379269 id: CMUH112-REC3-160 briefTitle: Effectiveness Verification of a Smartphone-based System for Assessment and Health Care on Myofascial Pain Syndrome overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-06 date: 2024-12 date: 2024-04-23 date: 2024-04-24 name: China Medical University Hospital class: OTHER name: National Cheng Kung University name: National Science and Technology Council briefSummary: Myofascial pain syndrome (MPS) is the most common musculoskeletal pain disorder. The pain originates from myofascial trigger points (TrPs) in skeletal muscle. The muscle that presents with TrPs would be identified through clinical diagnosis and assessment, and further treatment would be designed according to the identified muscle.With the high penetration rate of smartphones, it would be convenient to utilize smartphones as the assistive technology in the assessment and intervention of MPS. The smartphone-based MPS assessment and care system could eliminate the restrictions of the epidemic, and provide an independent usage, precisely identifying muscle with TrPs and personalized care plan application. Therefore, the purpose of this study is to 1. develop a smartphone-based assessment and health care system for patients with myofascial pain syndrome. And to 2. verify the feasibility and validity of the system assessment function. And to 3. testify the effectiveness of the system health care functions for patient intervention. conditions: Myofascial Pain Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: INVESTIGATOR count: 60 type: ESTIMATED name: App healthcare name: Control measure: current pain visual analogue scale measure: functional questionnaire sex: ALL minimumAge: 20 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06379256 id: 202400364B0 briefTitle: Evaluation of Immune Responses and Outcomes in Patients With Hepatocellular Carcinoma Undergoing Radiotherapy overallStatus: NOT_YET_RECRUITING date: 2024-04-26 date: 2029-03-17 date: 2032-03-17 date: 2024-04-23 date: 2024-04-23 name: Chang Gung Memorial Hospital class: OTHER briefSummary: Radiation therapy (RT) is a highly effective modality for managing localized solid tumors and has become a fundamental component of treating unresectable hepatocellular carcinoma (HCC). Our previous preclinical investigation (Hsieh et al., Science Immunology 2022) revealed that RT can initiate immunogenic cell death and facilitate the cross-presentation of tumor antigens by antigen-presenting cells, thereby augmenting systemic anti-tumor T cell responses in murine tumor models. However, this immune response subsequent to irradiation has not been comprehensively evaluated in clinical trials involving HCC patients. Given that RT represents a standard therapeutic approach for unresectable HCC, our ongoing phase II non-randomized trial aims to prospectively assess immunological responses and dose-volumetric parameters, while identifying predictors of clinical outcomes in patients undergoing definitive RT for HCC. conditions: Hepatocellular Carcinoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 300 type: ESTIMATED name: Photon or proton radiotherapy measure: Progression free survival (PFS) measure: Local control (LC) measure: Time to progression (TTP) measure: Overall Response Rate (ORR) measure: Overall survival (OS) measure: Incidence and severity of adverse events sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Chang Gung Memorial Hospital at Linkou city: Taoyuan City zip: 333 country: Taiwan lat: 24.95233 lon: 121.20193 hasResults: False
nctId: NCT06379243 id: KY-2023-008-02 briefTitle: Development and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures overallStatus: RECRUITING date: 2023-12-01 date: 2026-12-31 date: 2027-12-31 date: 2024-04-23 date: 2024-04-23 name: The Seventh Affiliated Hospital of Sun Yat-sen University class: OTHER name: The Fourth Affiliated Hospital of Guangzhou Medical University name: Huizhou Municipal Central Hospital name: Dongguan Hospital of Traditional Chinese Medicine briefSummary: In this project, IDEAL-IQ technology and PDFF and R2\* image-based imaging methods are used to analyze the intrinsic relationship between preoperative vertebral bone marrow fat content, magnetic susceptibility properties of bone tissue and bone strength (bone volume and bone mass), to explore the mechanism of vertebral re-fracture after PVP / PKP, and to explore the imaging markers for the risk of postoperative vertebral re-fracture after PVP / PKP. To construct a precise and individualized risk assessment model of vertebral re-fracture after PVP/ PKP by combining clinical risk factors, preoperative quantitative MRI parameters (PDFF, R2\*) and imaging characteristics, so as to achieve the goal of objectively and accurately evaluating the risk of vertebral re-fracture at the early stage of the postoperative period (1 year). conditions: Osteoporosis Fracture conditions: Osteoporosis Vertebral conditions: Compression Fracture conditions: Perform PVP / PKP Treatment studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 560 type: ESTIMATED name: PVP/PKP measure: Non-operative vertebral re-fracture within 1 year after PVP / PKP measure: Visual Analog Score (VAS) at 1 year after PVP/ PKP measure: Oswestry Dysfunction Index (ODI) at 1 year after PVP/PKP sex: ALL minimumAge: 50 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Seventh Affiliated Hospital, Sun Yat-sen University status: RECRUITING city: Guangzhou state: Guangdong country: China name: Kuiqing Lu role: CONTACT phone: 0755-81207263 email: lukq@mail.sysu.edu.cn lat: 23.11667 lon: 113.25 hasResults: False
nctId: NCT06379230 id: SH9H-2023-T378-1 briefTitle: A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE) overallStatus: RECRUITING date: 2019-01-01 date: 2022-12-31 date: 2025-02-28 date: 2024-04-23 date: 2024-04-23 name: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University class: OTHER briefSummary: Background/Rationale: Neurofibromatosis type 1 (NF1) affects about 1 in every 3000 people worldwide. Globally, 30\~50% NF1 patients will develop plexiform neurofibromas (PNs), which grow rapidly in early childhood and can cause disfigurement, motor dysfunction, pain, airway dysfunction, visual impairment and bladder and bowel dysfunction. This systemic disease imposes a heavy psychosomatic and financial burden on patients and their caregivers. In NF1 patients, the lifetime risk of MPNST developed from PN is 8% to 13%. The mean age for NF1-associated death was approximately 20 years lower than that for the general population. Limited epidemiological and clinical data of Chinese NF1 patients is available to date. And the treatment pattern of Chinese NF1-PN patients is also unknown.